Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

76.49 USD -1.42 (-1.82%)
Streaming Delayed Price Updated: 1:21 PM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 393,370
Open 77.50
Bid (Size) 76.47 (1)
Ask (Size) 76.54 (4)
Prev. Close 77.91
Today's Range 75.84 - 77.72
52wk Range 68.25 - 131.94
Shares Outstanding 176,713,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
Topline data expected to be available in mid-2022 
From PR Newswire
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
- Full-year 2020 Total Revenues Increased 9% to $1.86 billion 
From PR Newswire

Performance

YTD
-11.37%
-11.37%
1 Month
-7.84%
-7.84%
3 Month
-3.79%
-3.79%
6 Month
+0.64%
+0.64%
1 Year
-18.97%
-18.97%

More News

Read More
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
From PR Newswire
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
From PR Newswire
BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
From PR Newswire
BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
From PR Newswire
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
From PR Newswire
Noteworthy Friday Option Activity: BMRN, ZNGA, ZYXI
Tags Stocks
From Market News Video
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
From PR Newswire
Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
Tags Market News BMRN
From Motley Fool
Implied USMV Analyst Target Price: $73
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.